EGFR and non-small cell lung carcinoma: In this regard, we await the results of ongoing clinical trials investigating Dato-DXd in combination with osimertinib as a first-line therapy (TROPION-Lung14, NCT06350097) or following progression on osimertinib (TROPION-Lung15, NCT06417814) in patients with EGFR-mutated advanced NSCLC.